Blood Pressure Monitoring for Minoxidil Therapy in Alopecia Patients

Main Article Content

Colin Kincaid
UC Irvine

Justin Arnold
UC Irvine

Celine Phone
UC Irvine

Minjun Park
UC Irvine

Arash Babadjouni
UC Irvine

Natasha Mesinkovska
UC Irvine

Keywords

alopecia, blood pressure, low-dose oral minoxidil, androgenetic alopecia, alopecia areata

References

1. Jimenez-Cauhe J, Saceda-Corralo D, Hermosa-Gelbard A, et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022;87(6):e235-e237. doi:10.1016/j.jaad.2022.06.1205

2. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. doi:10.1016/j.jaad.2021.02.054

3. Panchaprateep R, Lueangarun S. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther (Heidelb). 2020;10(6):1345-1357. doi:10.1007/s13555-020-00448-x

4. Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000Res. 2017;6:1650. doi:10.12688/f1000research.11775.1

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.6.6

Article Details

How to Cite
Kincaid, C., Arnold, J., Phone, C., Park, M., Babadjouni, A., & Mesinkovska, N. (2023). Blood Pressure Monitoring for Minoxidil Therapy in Alopecia Patients. SKIN The Journal of Cutaneous Medicine, 7(6), 1123–1125. https://doi.org/10.25251/skin.7.6.6
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Research Letters
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.